Right-to-try drug bill signed into state law
Terminally ill patients in Indiana who have run out of FDA-approved options can now turn to treatments and medicines in the testing phase.
Medical Research
Articles
Potential Alzheimer’s drug further backs protein hypothesis
The results of an experimental drug for Alzheimer’s disease provide the best evidence so far that the memory-robbing condition is caused by an errant protein in the brain. Drugmakers including Eli Lilly have been concentrating their Alzheimer’s research on that area.
How Eli Lilly CEO Lechleiter pulled company out of long slide
After weathering a barrage of patent expirations, the pharmaceutical giant has restocked its pipeline and is positioned to grow.
Lilly to pay AstraZeneca up to $500M in Alzheimer’s push
The two companies will work together to develop AZD3293, which belongs to a novel class of drugs called BACE inhibitors that block production of amyloid, a protein that causes plaque to build up in the brain of Alzheimer’s patients.
Recent wins worth $4B to Lilly market value
Lilly is finally putting meat on the bones of its predictions about its experimental diabetes and cancer drugs. That gives investors the certainty they crave that Lilly’s future revenue won’t remain in its 2014 doldrums.
After strong trials, Lilly to seek approvals for psoriasis drug
The drug company said Thursday its drug ixekizumab cleared away skin inflammation in six times as many patients as the blockbuster drug Enbrel. Lilly is in a race to bring the first in a new-class of psoriasis treatments to market.
Regenstrief plans new $13M headquarters
Regenstrief, a not-for-profit medical research organization, plans to move 50 investigators, 165 staff members and a number of affiliated scientists into the building when it is completed in mid-2015.
Indy startup has rare disease in its sights
Founders of Chondrial Therapeutics believe that if further testing validates their treatment for Friedreich’s ataxia, it could be a blockbuster with annual sales topping $1 billion.
WellPoint unit launching $80M information exchange
Two insurers announced Tuesday that they are partnering for an ambitious project to establish one of the nation's largest health-information exchanges, an effort they hope will reduce duplication and improve patient outcomes.
Roche drug trial backs Lilly on Alzheimer’s findings
Results of a Roche clinical trial mirror those produced by an experimental Lilly drug two years ago. Lilly executives say that validates their approach in the multi-billion-dollar race to market the first drug to reverse Alzheimer’s.
Regenstrief taps Deloitte to pick up more health care industry clients
With federal health research funding in decline, Indianapolis-based Regenstrief Institute Inc. wants to make up the difference by serving pharmaceutical companies, medical device makers, health insurers and hospital systems.
Discovery may be key to Alzheimer’s treatment
Scientists have discovered that a gene-regulating protein that protects the developing brain of a fetus resurfaces in old age and may stave off dementia, a finding that could open a new path in Alzheimer’s research.
Deals up, dollars down in 2013 for Indiana life sciences firms
Venture capitalists and angel investors put a combined $31.9 million into 18 life sciences companies last year, with some of the largest amounts going to Nextremity Solutions, hc1.com and FAST BioMedical.
Three groups puzzled by woman’s $7 million bequest
The organizations which include Indianapolis-based Hoosier Oncology Group have no idea why an Evansville teacher chose them as beneficiaries.
Lilly invests in NY life sciences venture capital initiative
Indianapolis-based Eli Lilly and Co. has joined two other companies to contribute $40 million to an early-stage life sciences venture capital initiative in New York City.
Purdue makes big push into state’s pharma industry
With a $60 million-plus investment, the university aims to take molecules from discovery to clinical trials.
VC headwinds continue for life sciences firms
Indiana life sciences companies trying to raise venture capital continue to do so with a national wind in their faces, according to the third-quarter venture capital data.
IU med school’s research efforts have multiplied, but so have peers’
Retiring Indiana University School of Medicine Dean Dr. Craig Brater has, in his 13-year tenure, doubled the school’s number of research-oriented faculty to 700, doubled the amount of space for them to work in, and doubled the revenue from research grants and contracts. But all that effort has hardly budged IU in national rankings.
Lilly aims potential Alzheimer’s drug at early patients
The trial of 2,100 patients, called Expedition III, will use new measures of cognitive function, such as the ability to do tasks like cooking or driving, or remembering words after a delay.
Lilly drug for Alzheimer’s gets limited Medicare coverage
Lilly officials said they will push ahead with the first-of-a-kind imaging chemical, despite the mostly negative ruling by Medicare officials.